Completed PHASE2 INTERVENTIONAL 3-arm NCT02294552

Post-transplantation Cyclophosphamide as GVHD Prophylaxis After HSCT

High-dose Post-transplantation Cyclophosphamide as Graft Versus-host Disease Prophylaxis After Allogeneic Hematopoietic Stem Cell Transplantation

Sponsor: Ivan S Moiseev

Conditions Acute Lymphoid Leukemia Acute Myeloid Leukemia Chronic Lymphocytic Leukemia Immune System Diseases Lymphoma Myelodysplastic Syndromes

Interventions Allogeneic hematopoietic stem cell transplantation Busulfan Cyclophosphamide Fludarabine monophosphate Mycophenolate mofetil Tacrolimus

Updated 7 times since 2017 Last updated: Jan 12, 2018 Started: Oct 31, 2014 Primary completion: Nov 30, 2016 Completion: Nov 30, 2017

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT02294552, this PHASE2 trial focuses on Acute Lymphoid Leukemia and Acute Myeloid Leukemia and remains completed. Sponsored by Ivan S Moiseev, it has been updated 7 times since 2014, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.

Status Flow

Change History

7 versions recorded

Sep 2025 — Present [monthly]

Completed PHASE2
Sep 2024 — Sep 2025 [monthly]

Completed PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE2
Jan 2021 — Jul 2024 [monthly]

Completed PHASE2
Jun 2018 — Jan 2021 [monthly]

Completed PHASE2

▶ Show 2 earlier versions

Feb 2018 — Jun 2018 [monthly]

Completed PHASE2

Status: Active Not Recruiting → Completed
Jan 2017 — Feb 2018 [monthly]

Active Not Recruiting PHASE2

First recorded

Oct 2014

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Ivan S Moiseev

Data source: St. Petersburg State Pavlov Medical University

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Saint Petersburg, Russia